|
Tests Its Oral Insulin Capsule on Healthy Human Volunteers
JERUSALEM, Israel | January 22, 2008 | Oramed Pharmaceuticals, Inc. (OTCBB: ORMP – http://www.oramed.com), a developer of oral delivery systems, has begun Phase 1B clinical trials for its oral insulin capsule. This Phase 1B trial is focused on finding the optimal dosage for the formulation of Oramed’s proprietary oral insulin delivery technology. The study utilizes healthy human volunteers in order to determine the final formulation of the oral insulin product. This trial is a continuation of Oramed’s successfully completed Phase 1A trials, which were conducted on healthy volunteers
“Oramed is excited to move forward with our lead drug candidate,” commented Nadav Kidron, Chief Executive Officer of Oramed. “This phase of the trial, following the successful completion of our Phase 1A trials, is a significant milestone for Oramed and for our oral insulin product. We are pleased to be one step closer to our goal of offering the many diabetes patients around the world a viable oral insulin solution.”
About Oramed Pharmaceuticals
Oramed Pharmaceuticals’ is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimens. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines. For more information please visit our website at: www.oramed.com.
Legal Notice and Forward Looking Statements For Oramed Pharmaceuticals:
Certain of the statements contained in this press release, including the statement “the Company’s goal is for the completion of formal phase I studies by the 3rd quarter of 2008”, are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the Company’s filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.
SOURCE: ORAMED PHARMACEUTICALS |
